Drug profile

The FDA adverse-event record for Canine Influenza Virus H3N2

37 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Influenza Virus H3N2. See the species affected, top reactions, and outcomes below.

37
adverse-event reports
10.8%
death-coded share
Dog
most-reported species
18
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
37
Total Reports
4
Deaths Reported
10.8%
Death Rate

Active Ingredients

Canine Influenza Virus H3N2

Administration Routes

Subcutaneous

Species Affected

Dog 37

Most Affected Breeds

Maltese 5
Schnauzer - Miniature 4
Retriever - Labrador 3
Shih Tzu 2
Dachshund - Standard Long-haired 2
Terrier - Bull - American Pit 2
Boxer (German Boxer) 2
Shepherd Dog - German 2
Beagle 2
Retriever - Golden 2

Most Reported Reactions

Vomiting 18
Anaphylaxis 11
Pale mucous membrane 7
Lethargy (see also Central nervous system depression in 'Neurological') 6
Diarrhoea 6
Facial swelling (see also 'Skin') 6
Collapse NOS (see also 'Cardio-vascular' and 'Neurological disorders') 4
Hives (see also 'Skin') 4
Tachycardia 3
Lack of efficacy - NOS 3
Bradycardia 3
Death 3

Outcome Breakdown

Ongoing
16 (43.2%)
Recovered/Normal
16 (43.2%)
Died
3 (8.1%)
Euthanized
1 (2.7%)
Outcome Unknown
1 (2.7%)

Canine Influenza Virus H3N2 Adverse Event Insights

37 reports name Canine Influenza Virus H3N2; 4 recorded a death outcome (10.8% of reported events, not a population-level mortality rate). Active ingredient: Canine Influenza Virus H3N2. Administration route: Subcutaneous.

By species: Dog (37 reports). By breed: Maltese (5), Schnauzer - Miniature (4), Retriever - Labrador (3).

Leading clinical signs: Vomiting (18), Anaphylaxis (11), Pale mucous membrane (7), Lethargy (see also Central nervous system depression in 'Neurological') (6). Outcome, 37 coded reports: Ongoing leads at 43.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.